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Abstract
We conducted a case-control study of renal cancer (987 cases and 1298 controls) in Central and Eastern Europe and
analyzed genomic DNA for 319 tagging single-nucleotide polymorphisms (SNPs) in 21 genes involved in cellular growth,
differentiation and apoptosis using an Illumina Oligo Pool All (OPA). A haplotype-based method (sliding window analysis of
consecutive SNPs) was used to identify chromosome regions of interest that remained significant at a false discovery rate of
10%. Subsequently, risk estimates were generated for regions with a high level of signal and individual SNPs by
unconditional logistic regression adjusting for age, gender and study center. Three regions containing genes associated
with renal cancer were identified: caspase 1/5/4/12(CASP 1/5/4/12), epidermal growth factor receptor (EGFR), and insulin-like
growth factor binding protein-3 (IGFBP3). We observed that individuals with CASP1/5/4/12 haplotype (spanning area
upstream of CASP1 through exon 2 of CASP5) GGGCTCAGT were at higher risk of renal cancer compared to individuals with
the most common haplotype (OR:1.40, 95% CI:1.10–1.78, p-value = 0.007). Analysis of EGFR revealed three strong signals
within intron 1, particularly a region centered around rs759158 with a global p = 0.006 (GGG: OR:1.26, 95% CI:1.04–1.53 and
ATG: OR:1.55, 95% CI:1.14–2.11). A region in IGFBP3 was also associated with increased risk (global p = 0.04). In addition, the
number of statistically significant (p-value,0.05) SNP associations observed within these three genes was higher than
would be expected by chance on a gene level. To our knowledge, this is the first study to evaluate these genes in relation to
renal cancer and there is need to replicate and extend our findings. The specific regions associated with risk may have
particular relevance for gene function and/or carcinogenesis. In conclusion, our evaluation has identified common genetic
variants in CASP1, CASP5, EGFR, and IGFBP3 that could be associated with renal cancer risk.
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Introduction
Renal cancer is among the most commonly diagnosed cancers
in men and women in the United States [1] and Eastern Europe
[2]. The incidence of renal cell carcinoma (RCC), the most
common malignancy of renal cancer, has increased rapidly
worldwide over the past few decades [3,4] with some of the
highest rates occurring in Central and Eastern Europe [2,5]. Only
a few well-established lifestyle risk factors have been identified:
cigarette smoking, obesity, hypertension and diabetes [6]. An
increased risk observed among those with a family history of renal
cancer and the identification of inherited forms of kidney cancer
provide justification for evaluating the genetic susceptibility of this
disease, which has not been fully investigated [6].
The mechanism by which a normal cell progresses to carcinoma
customarily involves the disruption of critical molecular pathways in
cellular growth, differentiation, and development [7]. Among the
steps required for tumor cell growth and survival are the
amplification of signals from growth factors and the interruption of
signals promoting cell death or apoptosis [8,9]. Alterations in genes
involved in such pathways are thus likely to contribute to cancer risk.
Based on this logic, we identified genes involved in cell growth and
differentiation (AKR1C3, EGF, EGFR, IGFBP3, IGFBP5, PPARG,
TGFA, VCAM1, and VEGF) and apoptosis (CASP1, CASP2, CASP3,
CASP4, CASP5, CASP6, CASP7, CASP8, CASP9, CASP10, CASP12,
and CASP14; Table 1). Several of these genes have been associated
with risk of cancer at other sites [10,11]; however, the role of these
genes in the development of renal cancer remains unknown.
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Given the importance of these pathways in carcinogenesis and
the lack of studies evaluating genetic susceptibility and renal
cancer, we evaluated whether polymorphisms in these 21 genes
could alter the risk for developing renal cancer in a large multi-
center case-control study based in Central and Eastern Europe.
We hypothesized that common variation in genes involved in
cellular growth, differentiation and apoptosis may increase genetic
susceptibility to renal cancer.
Methods
Study Population
The Central and Eastern European Renal Cancer (CEERC)
Study is a hospital-based case-control study of renal cancer (1,097
cases and 1,555 controls) that was conducted in seven centers in
Eastern and Central Europe (Moscow, Russia; Bucharest,
Romania; Lodz, Poland; and Prague, Olomouc, Ceske Budejovice
and Brno, Czech Republic). Details of the study have been
described previously [12]. Newly diagnosed and histologically
confirmed cases of renal cancer (ICD-0-2 code C64) between the
ages of 20 and 79 years were recruited from August 1999 through
January 2003. Trained medical staff reviewed medical records and
extracted information on date and method of diagnosis,
histological classification, tumor location, stage and grade.
Pathology data was available for 917 cases. RCC was defined as
the following subtypes: clear cell, clear cell with papillary features,
clear cell with sarcomatoid, papillary type I, papillary non-type I,
papillary type II, chromophobe and hybrid subtype (n = 848).
Clear cell renal cancer was defined as the first three clear cell
subtypes (n = 760). Eligible controls were chosen from among
patients admitted to the same hospital as cases for conditions
unrelated to smoking or genitourinary disorders (except for benign
prostatic hyperplasia) and were frequency-matched to cases on age
(within 3 years), sex, and study center. Among controls, the disease
conditions associated with hospitalization were the following:
obstetric or perinatal (0.1%), infectious (1%), psychiatric (1%),
endocrine (2%), hematologic (3%), dermatologic (3%), injury or
poisoning (3%), genitourinary (benign prostatic hyperplasia (4%),
pulmonary (4%), orthopedic or rheumatologic (9%), cardiovascu-
lar (10%), neurologic (11%), ophthalmologic or otologic (14%),
Table 1. Description of selected genes and tagging SNPs.
Name of Gene Function
Chromosome
Location
Number of tagSNPs1/
tagSNPs p,0.052
Adjusted
min P test
Growth and Differentiation Genes
AKR1C3 - Aldo-keto Reductase
Family 1, Member C3
Catalyzes the reduction of prostaglandin (PGD). Role in cell differentiation
by diverting conversion of PGD from PGJ2 to PGF2.
10p15-p14 17/1 0.57
EGFR -Epidermal Growth Factor
Receptor
A transmembrane growth factor receptor. EGFR binding leads to the
activation of major signal transduction pathways involved in regulating
cell proliferation, differentiation, migration and survival.
7p12 65/12* 0.48
EGF - Epidermal Growth Factor EGF is a mitogenic factor and an important ligand for EGFR. Subsequently
has a major effect on cell differentiation.
4q25 16/0 0.90
IGFBP3 - Insulin-like Growth
Factor Binding Protein 3
Main carrier of circulating IGFs. Independently, has a key role in
regulating cell proliferation and apoptosis.
7p13-p12 14/3* 0.23
IGFBP5 - Insulin-like Growth
Factor Binding Protein 5
Another carrier for IGF. Role in regulating cell survival, differentiation,
and apoptosis.
2q33-q36 17/1 0.34
PPARG- Peroxisome Proliferator-
activated Receptor Gamma
A nuclear hormone receptor. When dimerizes with retinoid X receptor,
regulates transcription of numerous genes. Also a regulator of adipocyte
differentiation
3p25 26/1 0.66
TGFA -Transforming Growth
Factor, alpha
Growth factor that competes with EGF in binding to EGFR 2p13 39/1 0.76
VCAM1 - Vascular Cell Adhesion
Molecule 1
Member of the immunoglobulin family and encodes a cell surface
glycoprotein expressed by cytokine-activated endothelial cells
1p32-p31 14/1 0.41
VEGF - Vascular Endothelial
Growth Factor A
Important growth factor in angiogenesis and tumor growth 6p12 21/1 0.78
Apoptosis Genes
CASP1/5/4/12 A member of the cysteine-aspartic acid protease (caspase) family which
plays an integral role in a complex cascade of events that regulate cell
apoptosis
11q22.2-22.3 24/5* 0.26
CASP2 Member of the caspase family 7q34-q35 6/0 0.90
CASP3 Member of the caspase family 4q34 10/0 0.83
CASP6 Member of the caspase family 4q25 7/0 0.77
CASP7 Member of the caspase family 10q25 16/0 0.85
CASP8/10 Member of the caspase family 2q33-q34 12/0 0.85
CASP9 Member of the caspase family 1p36.3-p36.1 7/0 0.96
CASP14 Member of the caspase family 19p13 8/1 0.25
1rs numbers for SNPs can be found in supplementary table 1.
2TagSNPs with p-value for trend ,0.05.
*indicates genes where number of tagSNPs with p-value for trend ,0.05 is more than one would expect to see by chance.
doi:10.1371/journal.pone.0004895.t001
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gastrointestinal (19%), and other (16%). No single disease made up
more than 20% of the control group. A portion of the controls
were also recruited for a parallel study of lung cancer. All recruited
cases and controls were Caucasian. Response rates at each center
ranged from 90.0 to 98.6% for cases and from 90.3 to 96.1% for
controls.
Interviews were conducted by trained personnel to collect
standardized lifestyle and food frequency questionnaires. Data was
collected on demographic characteristics, education, tobacco
smoke exposures, alcohol consumption, dietary practices, anthro-
pometry, medical history, family history, and occupational history.
Blood samples were collected and stored at 280uC and shipped
to the National Cancer Institute (NCI). Genomic DNA was
extracted from whole blood buffy coat by the standard phenol
chloroform method at the NCI laboratory. All subjects in this
study provided written informed consent. This study was approved
by the institutional review boards (IRB) at the NCI, International
Agency for Research on Cancer (IARC), and each participating
center.
Genotyping
We analyzed 319 tagging single-nucleotide polymorphisms
(SNPs) in 21 genes involved in cellular growth, differentiation
(AKR1C3, EGFR, EGF, IGFBP3, IGFBP5, PPARG, TGFA, VCAM1,
VEGF) and apoptosis (CASP1, CASP5, CASP4, CASP12, CASP2,
CASP3, CASP6, CASP7, CASP8, CASP10, CASP9, CASP14) that we
hypothesized could increase RCC risk (Table 1). Since several of
the caspase genes were located relatively close to each other,
tagSNPs were chosen to comprehensively assess the variation in
the region rather than just the gene (CASP1/5/4/12 and CASP8/
10). TagSNPs were selected from among common variants (minor
allele frequencies $5%) found in Caucasians using a tagSNP
method [13] with an r2.0.80 to provide high genomic coverage.
In addition, important nonsynonymous SNPs or those with
potential functional significance were included. All SNPs are
reported in the NCI SNP500Cancer database (http://snp500can-
cer.nci.nih.gov)[14]. Genotyping was conducted at NCI’s Core
Genotyping Facility where staff was blinded to case/control status
and duplicate quality control samples (5% samples) interspersed
among plates. All genotyping was performed using an Illumina
GoldenGate H Oligo Pool All (OPA) assay, which was designed
using publicly available sequencing information. The genotype
frequencies among controls showed no deviation from the
expected Hardy-Weinberg equilibrium proportions (p.0.05). All
SNPs had a genotyping completion rate .98% except for
rs3770472 (96%). The quality control concordance rates were
.97% for all SNPs except for rs10885493 (92%), rs12416109
(92%), rs10752001 (94%), and rs13392762 (94%).
Replication Study
The US Kidney Cancer Study is a population-based case-
control study conducted in Detroit and Chicago. Cases were
residents of the study areas, aged 20 to 79 years who were newly
diagnosed with histologically confirmed renal cell carcinoma
(ICD-O2 C64.9) from February 2002 through January 2007.
Controls were frequency-matched to cases by study center, race,
age, and sex. Controls aged 65 years and older were identified
from Medicare files, and those under age 65 years were identified
from Division of Motor Vehicle records. African American cases
and controls were over-sampled. Written informed consent was
obtained from all participants, and IRB approvals were obtained
from all participating study centers.
Participants were interviewed by trained interviewers to elicit
information on demographic factors, use of tobacco and alcohol,
diet, occupational history, height and weight history, family history
of cancer, reproductive history among women, medical history,
and medication history including the use of diet pills and
antihypertensives. A total of 1568 Caucasians (856 cases and
712 controls) and 884 African-Americans (523 cases and 361
controls) were interviewed. Of these subjects, 1109 cases and 1106
controls provided DNA that was extracted using standard
procedures. Genotyping data was available for 966 cases and
977 controls with sufficient quality and quantity of DNA. Subjects
were predominantly recruited from the Detroit area (84%), and
were similar in age (76%.50 years) and sex (57% male) to those in
the CEERC study.
Statistical Analyses
Of the 987 cases and 1298 controls that had valid study data
and provided genomic DNA, analyses were based on the 777 cases
and 1035 controls that had adequate quality DNA and were
successfully genotyped on the OPA platform in the CEERC study.
Associations were evaluated through several methods. Global p-
values were evaluated using the minimum-p value permutation
test [15]. A haplotype-based method called HaploWalk, conducted
in Matlab, was used to identify chromosome regions of interest by
examining regional associations rather than effects from an
individual SNP. For a gene with K SNPs, the HaploWalk
procedure considered a 3 SNP sliding window for each SNP from
SNP 2 through SNP K-1. To account for multiple testing across
the K SNPs, the K-2 p-values (one for each window) were adjusted
for multiple comparisons using the False Discovery Rate (FDR)-
controlling procedure of Benjamini and Hochberg [16]. Windows
that remained significant at a FDR level of 10% were considered
to be a candidate region of interest. If adjacent windows were
significant, they were amalgamated into a single candidate region
of interest. Haplotypes in the candidate block were then
reconstructed and effects evaluated using Haplostats (Version
1.3.1) in R (version 2.4.1). The most common haplotype was used
as the reference group and haplotypes with frequencies less than
1% were combined into one category for testing. Subsequently,
unadjusted and adjusted (age, sex, and study center) odds ratios
(OR) and 95% confidence intervals (95% CI) using the log-
additive model were generated for regions with a high level of
signal.
The association between individual SNPs and risk of renal
cancer were estimated by unconditional logistic regression,
adjusted for age, sex, and study center. Genotypes were evaluated
by coding the homozygous common allele as the referent group
and separately comparing the heterozygous and homozygous rare
allele genotypes to the referent group. Linear tests for trends were
conducted by including a variable coded 0, 1, and 2 corresponding
to the number of rare alleles. Associations for SNPs were
considered robust if they were significant (based on the p-value
of the test for trend) with a FDR level of 20% or less. A more
liberal FDR level was chosen at this stage of analysis in order to
guide us toward SNPs that may be of interest within previously
identified regions of interest. FDR adjustment was based on the
number of SNPs within each gene region. Additional adjustment
for potential confounders (body mass index [BMI], self-reported
hypertension, and smoking) did not result in meaningful changes
of the risk estimates and were not included in the analyses. In
addition, we investigated multiplicative interaction between
individual SNPs and age, sex, and BMI, using the likelihood ratio
test to compare the fit of models with and without interaction
terms. Heterogeneity of genotype frequencies among countries
was evaluated by using the likelihood ratio test to compare the fit
of models with and without interaction terms, but we did not find
Renal Cancer Susceptibility
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any evidence of heterogeneity. Analyses were conducted using
SAS version 9.1 (SAS Institute, Cary, NC).
Results
A large proportion of the study population was from the Czech
Republic, with a slightly higher proportion among cases (Table 2).
Controls were more likely to be male, but were similar to cases in
age distribution. Cases were more likely than controls to have
higher BMI, have a family history of cancer, and report
hypertension.
Results from global gene-based tests of association are included
in Table 1. Among results from the minimum p-value test, CASP1/
5/4/12, CASP14, and IGFBP3 were the most promising gene
regions, but were not significant after adjustment for multiplicity
(total number of SNPs) over the entire gene (Table 1). However,
CASP1/5/4/12, EGFR, and IGFBP3 had a larger number of
significant SNPs (p-value for trend ,0.05) than one would expect
to see by chance. In addition, with a haplotype-based sliding
window method, we identified the same genes with regions that
were associated with renal cancer risk at a FDR level ,10%:
CASP1/5/4/12, EGFR, IGFBP3, and VCAM1 (Supplementary
Figures S1, S2, S3).
An interesting region was detected that spans over the area
upstream of CASP1 through exon 2 of CASP5 (Supplementary
Figure S1). At this region, individuals with a specific variant
haplotype GGGCTCAGT (OR: 1.40, 95% CI: 1.10–1.78) had a
1.4 fold higher risk of renal cancer compared to those with the
most common haplotype (Table 3). Concordant with the
haplotype analysis, several individual variants within this haplo-
type also had nominal statistically significant associations with
renal cancer risk (Table 4). After applying FDR adjustment, four
CASP1 and CASP5 SNPs (rs1785883, rs568910, rs492859 and
rs507879) were considered significant at a FDR level ,20%. The
strongest association among individual SNPs was rs507879
(Thr90Ala), located in exon 2 of CASP5. The ORs (95% CI) for
heterozygote and homozygote rare genotypes compared to the
homozygote common genotypes were 1.29 (1.03–1.60) and 1.39
(1.07–1.82; p-value for trend= 0.01), respectively. The OR and p-
value of the specific variant haplotype were stronger than the
associations (p-value for trend) observed for any of the individual
SNPs in this region, suggesting that the causal variant within this
haplotype may not have been genotyped.
We had the opportunity to conduct a quick replication of our
most statistically significant finding, CASP5 SNP rs507879 in the
US Kidney Cancer Study population (Table 5). Although results
from the US Kidney Cancer Study were not statistically
significant, the point estimates were in the same direction as those
from the CEERC study. A pooled estimate of 1.22 (95% CI: 1.04–
1.42) was observed for those with at least one copy of the rare
allele of rs507879 among Caucasian participants. A pooled
estimate including both Caucasians and African-Americans from
both studies was not noticeably different from the estimate
restricted to Caucasians (OR: 1.22, 95% CI: 1.05–1.41; Table 5).
A sliding window analysis over EGFR revealed three signals
within intron 1 (Supplementary Figure S2). In particular, two
haplotypes centered on rs759158 (region 3) were associated with a
higher risk of renal cancer (GGG: OR: 1.26, 95% CI: 1.04–1.53
and ATG: OR: 1.55, 95% CI: 1.14–2.11; Table 3) when
compared to the common haplotype. In the second EGFR region,
variant haplotype TGA was associated with an increased risk of
renal cancer compared to the common haplotype (OR: 1.32, 95%
CI: 1.02–1.70). Associations between three of the SNPs within
these EGFR haplotypes (rs11238349, rs6954351, and rs7796139)
were nominally statistically significant, but with FDR levels ,30%
(Table 4). The two SNPs rs6954351 and rs7796139 appear to be
responsible for the associations in their respective regions;
however, these associations do not appear to be entirely
independent effects as the SNPs are moderately correlated
(r2 = 0.47). We further evaluated the strong signal in EGFR by
integrating the second and third regions to form a haplotype
spanning seven SNPs in intron 1 (Supplementary Table S2).
Among common haplotypes, the effect estimates for haplotypes
containing GGG or GTG appear to be consistently above 1.0. It is
interesting to note that among common haplotypes in the
integrated region, the variant haplotype TGA from the second
region is present only with either variant haplotype GGG or GTG,
the statistically significant haplotypes from the third region. This
suggests that the two sets of haplotypes may be reflecting the same
signal. A strong haplotype effect was observed for the variant
haplotype TGA-A-GGG, with an OR of 1.84 (95% CI: 1.25–2.71)
and a p-value of 0.002. This effect was stronger than those
observed for the individual regions and reinforces the idea that
these two regions are related. A second variant haplotype in the
integrated region was also statistically significant (OR:1.60; 95%
Table 2. Distribution of demographic variables among
subjects in the Central and Eastern European Renal Cancer
study.
Cases Controls p-value
N % N %
All subjects 987 1298
Center
Bucharest, Romania 91 9.2 132 10.2
Lodz, Poland 81 8.2 197 15.2
Moscow, Russia 288 29.2 368 28.4
Czech Republic1 527 53.4 601 46.3 ,.0001
Sex
Male 589 59.7 838 64.6
Female 398 40.3 460 35.4 0.02
Age at Interview (y)
,50 163 16.5 228 17.6
$50 824 83.5 1070 82.4 0.51
Smoking Status
Never 454 46.1 528 40.7
Former 225 22.9 316 24.4
Current 305 31.0 452 34.9 0.03
Body Mass Index (kg/m2)
,25 288 29.2 457 35.4
25–30 429 43.5 556 43.1
30+ 270 27.4 278 21.5 0.001
Family history of cancer2
No 654 66.3 932 71.8
Yes 333 33.7 366 28.2 0.004
Self-Reported Hypertension
No 539 54.7 800 61.7
Yes 447 45.3 497 38.3 0.001
1Four centers: Brno, Olomuc, Prague, and Ceske.
2First degree relative with any cancer.
doi:10.1371/journal.pone.0004895.t002
Renal Cancer Susceptibility
PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4895
Table 3. Haplotype associations and Renal Cancer Risk.
Gene/Haplotypes Cases (%) Controls (%) OR1 95% CI
Unadjusted
p-value
Adjusted
p-value1
CASP1/5/4/12 haplotype
Region 1 (chr11: 104429456-104390522)
G-G-G-T-T-A-C-G-T 41.8 45.0 1.00
G-G-G-T-C-A-C-A-C 28.1 26.7 1.14 0.97–1.34 0.12
G-G-G-C-T-C-A-G-C 10.6 8.1 1.40 1.10–1.78 0.007
A-G-G-T-T-A-C-G-T 5.5 7.4 0.80 0.60–1.07 0.13
Global p-value 0.14 0.16
EGFR haplotype
Region 1 (chr7 55122130-55123913)
C-G-T 36.8 36.0 1.00
C-A-A 21.8 24.7 0.87 0.73–1.03 0.09
T-G-T 20.1 21.2 0.93 0.78–1.12 0.20
C-G-A 21.4 18.1 1.13 0.94–1.36 0.40
Global p-value 0.04 0.06
Region 2 (chr 7 55129830-55138684)
C-G-G 29.5 29.9 1.00
T-A-G 25.0 25.9 0.99 0.82–1.18 0.88
T-G-G 16.7 17.3 1.00 0.79–1.26 0.98
C-A-G 11.3 12.1 0.94 0.72–1.24 0.67
T-G-A 11.1 8.5 1.32 1.02–1.70 0.03
C-G-A 6.4 6.4 1.07 0.76–1.52 0.70
Global p-value 0.31 0.30
Region 3 (chr 7 55143370-55147338)
A-T-G 34.4 38.4 1.00
A-G-G 22.6 22.7 1.11 0.91–1.34 0.30
G-G-G 20.8 18.7 1.26 1.04–1.53 0.02
A-T-A 12.3 11.8 1.14 0.90–1.43 0.28
G-T-G 9.7 7.0 1.55 1.14–2.11 0.005
Global p-value 0.007 0.006
IGFBP3 haplotype
Region 1 (chr 7 45940583-45921554)
T-A-A-T-T-C-A-G 38.5 38.1 1.00
T-A-A-G-C-C-A-A 19.8 21.5 0.94 0.78–1.13 0.52
T-A-A-T-C-C-A-G 15.3 17.9 0.87 0.71–1.05 0.15
T-A-G-T-C-G-A-A 19.6 16.9 1.17 0.98–1.41 0.08
T-G-A-T-T-C-A-G 3.6 3.3 1.07 0.73–1.58 0.73
A-A-G-T-C-G-A-A 1.3 1.0 1.13 0.60–2.11 0.70
Global p-value 0.19 0.21
Region 2 (chr 7 45918779-45916095)
T-G-C 48.6 51.3 1.00
A-G-C 18.6 15.2 1.27 1.06–1.54 0.01
T-G-T 13.8 15.4 0.93 0.75–1.16 0.54
T-A-C 14.3 14.5 1.02 0.82–1.27 0.83
T-A-T 4.7 3.1 1.62 1.05–2.51 0.03
Global p-value 0.03 0.04
VCAM1 haplotype
Region 1 (chr 1: 100961998-100966793)
C-A-C 45.3 45.9 1.00
C-C-C 18.8 17.4 1.10 0.89–1.35 0.40
C-A-T 20.3 16.5 1.25 1.01–1.54 0.04
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CI: 1.09–2.37), but we were unable to determine what was driving
this association.
For IGFBP3, a large region across the gene was considered
noteworthy using a sliding window analysis (Supplementary Figure
S3). Two regions were defined by evaluating linkage disequilib-
rium across the identified area. The second region, spanning the
area of exon 5 to 39 downstream of IGFBP3, was associated with a
global p-value of 0.04. Among haplotypes in this region, variant
haplotype AGC (OR: 1.27, 95% CI: 1.06–1.54) and TAT (OR:
1.62, 95% CI: 1.05–2.51) were associated with increased renal
cancer risk (Table 3). Among SNPs in the haplotype, rs6670 was
statistically significantly associated with renal cancer risk at a FDR
level ,20%. We observed a positive association between renal
cancer risk among subjects that had at least one copy of the rare
allele with an OR of 1.27 (95% CI: 1.04–1.56). The association for
haplotype AGC, which contains the rare allele for rs6670, was
slightly stronger than the effect observed for the individual SNP
and appears to be driven primarily by rs6670. The causal variant
for haplotype TAT, however, is not apparent, suggesting that the
causal variant was not genotyped in this study.
In VCAM1, a variant haplotype centered on rs3917010 was also
associated with an increased risk of renal cancer (CAT OR: 1.25,
95% CI: 1.01–1.54; Table 3). However, none of the VCAM1 SNPs
were significantly associated with renal cancer risk after FDR
adjustment. Although a statistically significant association was
observed, this association could be spurious as the effects observed
for the haplotype are not concordant with the individual SNP
associations within this haplotype (Supplementary Table S1).
Results for individual analyses of all SNPs can be found in
Supplemental Table S1. No statistically significant interactions
between our statistically significant SNPs and potential effect
modifiers (age, sex, and BMI) were detected (data not shown).
Additional sensitivity analyses restricted to RCC (n= 627 cases)
and clear cell RCC (n= 564 cases) did not meaningfully change
any of the previously detected associations (data not shown).
Discussion
In this study, we conducted an exploratory analysis of 319 SNPs
in or around 21 genes involved in cell growth/differentiation and
apoptosis pathways in relation to renal cancer risk. We identified
both haplotypes and SNPs in CASP1/5/4/12, EGFR, and IGFBP3
that were statistically significantly associated with risk of renal
cancer. Associations between SNPs in the other investigated cell
growth/differentiation and apoptosis pathway genes were weak
and less promising.
There is strong evidence supporting the biological relevance of
genetic variants in EGFR and IGFBP3 and renal cancer risk. EGFR
encodes for a transmembrane growth factor receptor that plays a
critical role in the signal transduction pathway regulating cell
proliferation, differentiation, and survival [17,18]. A recent study
has proposed an additional role for EGFR of interacting with and
stabilizing the sodium/glucose cotransporter 1 (SGLT1), thus
helping to maintain intracellular glucose levels in low extracellular
glucose environments and prevent cell death from occurring [19].
This is especially relevant to renal cancer, as both EGFR and
SGLT1 are expressed in the kidney, where glucose uptake is
important [20]. Altered glucose metabolism is one of the major
hypotheses thought to explain the association between diabetes
and renal cancer. Thus far, most studies have focused on
evaluating EGFR in relation to cancer progression and targeted
treatment [21,22]. It is interesting to note that the first intron of
EGFR (.120 kb) has been implicated as an important regulatory
area [21,23]. A highly polymorphic (CA)n repeat in intron 1 of
EGFR, about 1.5 kb downstream of exon 1, has been associated
with decreased EGFR transcription in multiple studies [24,25].
This microsatellite appears to be in linkage disequilibrium with
several SNPs of unknown function in the promoter region of this
gene, as well[26]. One of these variants (rs759171) was also
genotyped in this study, but not associated with renal cancer risk
(Supplementary Table S1). In this study, three SNPs (rs11238349,
rs6954351, and rs7796139) from intron 1 of EGFR and identified
through our initial screen were statistically significantly associated
with risk of renal cancer. Among these three SNPs, only rs6954351
and rs7796139 were moderately correlated (r2 = 0.47) with one
another. Subsequent analyses suggest that perhaps a haplotype
that includes these two SNPs may be driving the associations
found in this region. The mechanism through which these intronic
SNPs (or variants in linkage disequilibrium with these SNPs) might
affect renal cancer risk is unknown but they do reside within a
functionally relevant region of EGFR that has been associated with
decreased EGFR transcription and protein expression in humans.
Similar to our findings for EGFR, the IGFBP3 regions associated
with modified risk appear to be functionally important in cancer.
IGFBP3 encodes for IGF-binding protein 3 and is the primary
carrier of circulating IGF-1. A reduction in the amount of IGFBP3
available results in an increase in levels of free IGF-1, a factor
associated with growth, proliferation, and an elevated risk of
several cancers [27,28]. Independent of IGF-1, IGFBP3 has also
been shown to affect cell proliferation and apoptosis through its
interactions with several signaling pathways [29,30]. In relation to
renal cancer, experimental studies have demonstrated that IGFBP3
expression is increased among both clear cell renal tumors and
renal cancer cell lines [31,32]. The promoter region of IGFBP3 has
also been observed to be frequently hypermethylated in primary
renal cell tumors, but unmethhylated among normal cells [33]. We
Gene/Haplotypes Cases (%) Controls (%) OR1 95% CI
Unadjusted
p-value
Adjusted
p-value1
T-A-C 8.3 10.6 0.81 0.63–1.04 0.09
C-C-T 6.1 8.6 0.75 0.55–1.02 0.07
Global p-value 0.02 0.03
SNPs included within haplotype regions:
CASP1/5/4/12: region 1: rs1785883, rs508760, rs7934239, rs501626, rs11821722, rs568910, rs492859, rs3181318, rs507879.
EGFR: region 1: rs759169, rs11238349, rs12535226; region 2: rs11977660, rs6593205, rs6954351; region 3: rs7796139, rs759158, rs7796872.
IGFBP3: region 1: rs10235181, rs13232606, rs2453836, rs903889, rs924140, rs2471551, rs9282734, rs3110697; region 2: rs6670, rs13223993, rs2270628.
VCAM1 chr1: region 1: rs3917009, rs3917010, rs3176867.
1Adjusted for age, sex, and center.
doi:10.1371/journal.pone.0004895.t003
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observed a statistically significant increase in renal cancer risk with
rs6670 located in the 39 untranslated region (UTR) of IGFBP3.
Variants in the 39UTR could be involved in the stability and
Table 4. Association between Selected Polymorphisms and
Renal Cancer Risk.
SNP/Genotypes Cases Controls OR1 95% CI p-trend
CASP 1/5/4/12
CASP1
rs1785883 (*12058T.C)
GG 686 880 1.00
AG 85 145 0.75 0.56 1.00
AA 2 8 0.34 0.07 1.60 0.02
AG+AA 0.75 0.57 1.00
rs508760 (*12353A.C)
GG 658 893 1.00
GT 112 135 1.12 0.85 1.47
TT 4 6 1.05 0.29 3.81 0.45
GT+TT 1.13 0.87 1.48
rs7934239 (212676T.C)
GG 700 940 1.00
AG 74 90 1.11 0.80 1.54
AA 2 2 1.27 0.18 9.10 0.50
AG+AA 1.09 0.79 1.50
rs501626 (212291A.G)
TT 580 820 1.00
CT 183 199 1.30 1.04 1.64
CC 14 16 1.19 0.57 2.48 0.03
CT+CC 1.29 1.04 1.62
rs11821722 (211804G.A )
TT 396 548 1.00
CT 310 405 1.09 0.89 1.33
CC 70 81 1.21 0.85 1.71 0.23
CT+CC 1.11 0.92 1.34
rs568910 (IVS2+365T.G)
AA 518 744 1.00
AC 225 254 1.28 1.03 1.59
CC 31 35 1.24 0.75 2.05 0.03
AC+CC 1.28 1.05 1.57
CASP5
rs492859 (25645T.G)
CC 514 741 1.00
AC 227 251 1.31 1.06 1.62
AA 30 35 1.21 0.73 2.00 0.02
AC+AA 1.29 1.05 1.58
rs3181318 (2373 C.T)
GG 337 472 1.00
AG 349 457 1.09 0.90 1.33
AA 89 106 1.20 0.88 1.65 0.21
AG+AA 1.12 0.93 1.35
rs507879 (Ex2-118A.G, T90A)
TT 212 337 1.00
CT 381 481 1.29 1.03 1.60
CC 179 209 1.39 1.07 1.82 0.01
CT+CC 1.31 1.07 1.61
EGFR
rs11977660 (IVS1-47643T.C)
SNP/Genotypes Cases Controls OR1 95% CI p-trend
TT 220 285 1.00
CT 381 499 0.98 0.79 1.23
CC 176 251 0.88 0.68 1.15 0.37
CT+CC 0.95 0.77 1.17
rs6593205 (IVS1-41287A.G)
GG 310 414 1.00
AG 368 456 1.09 0.89 1.34
AA 98 164 0.80 0.60 1.07 0.37
AG+AA 1.02 0.84 1.23
rs6954351 (IVS1-38789G.A)
GG 522 752 1.00
AG 236 257 1.34 1.08 1.65
AA 18 26 1.04 0.56 1.93 0.03
AG+AA 1.31 1.07 1.61
rs7796139 (IVS1-34103A.G)
AA 370 543 1.00
AG 337 423 1.17 0.96 1.42
GG 70 68 1.52 1.06 2.18 0.02
AG+GG 1.21 1.00 1.46
rs759158 (IVS1-30770G.T)
TT 253 351 1.00
GT 372 502 1.03 0.83 1.27
GG 151 181 1.16 0.88 1.52 0.33
GT+GG 1.06 0.87 1.30
rs7796872 (IVS1-30135G.A)
GG 593 780 1.00
AG 170 236 0.94 0.75 1.18
AA 11 18 0.76 0.36 1.63 0.43
AG+AA 0.94 0.75 1.17
IGFBP3
rs6670 (Ex5-411A.T)
TT 514 740 1.00
AT 227 261 1.24 1.00 1.53
AA 30 31 1.40 0.84 2.36 0.03
AT+AA 1.27 1.04 1.56
rs13223993 (Ex5+615C.T )
GG 506 702 1.00
AG 247 294 1.15 0.94 1.42
AA 24 37 0.87 0.51 1.49 0.46
AG+AA 1.11 0.91 1.36
rs2270628 (4848 bp 39 of STPG.A)
CC 514 676 1.00
CT 230 319 0.94 0.77 1.16
TT 27 34 1.04 0.62 1.76 0.73
CT+TT 0.95 0.78 1.16
1Adjusted for age, sex, and center.
doi:10.1371/journal.pone.0004895.t004
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expression of mRNA [34]. IGFBP3 variation has been evaluated
with several other cancer sites [35], but this is the first study to
evaluate SNPs in relation to renal cancer. In association studies,
SNPs in IGFBP3 and IGF related genes (IGF-1 and IGFBP1) have
been related to circulating IGF-1 and IGFBP-3 levels [36,37].
IGFBP3 SNP rs6670 (A allele) was not directly associated with
IGFBP-3 levels but was weakly associated with a decreasing trend
in circulating IGF-1 levels [36]. This is not entirely consistent with
the positive association we observed with renal cancer in our study,
but suggests that further study is needed to clarify the associations
observed.
CASP1, CASP4, CASP5 and CASP12 belong to a caspase
subfamily called the inflammatory caspases, which are involved
in the maturation of inflammatory cytokines (Il-1b and IL-18) in
addition to their role in apoptotic pathways [9,38,39]. Despite
their involvement in two key carcinogenic pathways, inflammation
and apoptosis, few published reports have evaluated genetic
variation in these four caspase genes in relation to cancer. In our
study, three CASP1/5/4/12 SNPs (rs568910, rs492859, rs507879)
were associated with an increased risk of renal cancer, while one
SNP (rs1785883) was associated with a decreased risk. The four
SNPs were only weakly correlated with each other (r2,0.5), except
for rs492859 and rs568910 which were strongly correlated
(r2 = 0.99) within our data. The strongest individual SNP
association with renal cancer was observed with rs507879, located
within exon 2 of CASP5 and results in a missense mutation and
amino acid substitution (Thr90Ala). The function of this particular
exon 2 SNP is unclear and is predicted to be a benign mutation by
PolyPhen. However, a common somatic mutation in exon 2 has
also been identified in leukemias and, gastric, colon, and lung
cancers, but has not yet been examined in renal tumors [40–43]. A
somatic mutation in a mononucleotide repeat (A)10 in exon 2
produces a shift in the reading frame during transcription resulting
in a premature stop and a truncated protein. This suggests that this
region in CASP5 may be particularly important for carcinogenesis.
To our knowledge, this is the first study to evaluate SNPs in all
but two of these growth/differentiation and apoptosis genes in
relation to renal cancer. The primary focus so far in the area of
renal cancer susceptibility has been on genetic variants in
xenobiotic metabolism genes [12,44] and the von Hippel-Lindau
(VHL) gene, which leads to an increased risk of the hereditary form
of renal cancer [45], Only three small studies have evaluated
variants in PPARG and VEGF in relation to renal cancer. Smith et al.
(n= 40 cases) observed that the rare allele of the PPARG P12A
polymorphism (rs1801282) was underrepresented among RCC
patients compared to controls, with an OR for trend of 0.28
(0.08–1.01) [46]. This finding is consistent with results from our
analysis (OR for trend: 0.80; 95% CI: 0.67–0.96), but this SNP was
not considered statistically significant after FDR adjustment. Kawai
et al. (n= 213 cases) [47] observed a weak association between three
VEGF promoter polymorphisms (rs1570360, rs2010963, rs699947)
and renal cancer progression and prognosis; and Abe et al. (n= 145
cases) [48] observed a nonsignificant association between three
VEGF 39UTR polymorphisms (C702T 2dbSNP identifier number
is unknown, rs3025039, rs10434) and renal cancer risk in Japanese
populations. Three of these SNPs were genotyped in our study
(rs2010963, rs699947, rs3025039), but only SNP rs699947
demonstrated a weak but nonsignificant association with renal
cancer risk. Our analysis of VEGF revealed only one nominally
significant SNP in the promoter region (rs833058; Supplemental
Table S1) which is correlated with rs699947 (r2 = 0.65).
A strength of our study is the large sample size which provides
sufficient statistical power to detect associations between SNPs and
renal cancer risk. Hospital-based controls in our study could
potentially cause selection bias if carrying specific genetic variants
were somehow related to hospitalization or if the controls were
somehow not representative of the general population. However,
the high participation and response rates among both cases and
controls minimize the potential for selection bias. Given the
multiple centers and countries in our study, the potential for
population stratification exists; however, we found no evidence of
heterogeneity. Population stratification may still be present, but
the likelihood of this is small among European populations [49].
Although tagSNP selection was not based on resequencing data,
the strategy for selecting tagSNPs allowed a more comprehensive
analysis of common genetic variation in these genes than the
traditional candidate SNP approach. Given the large number of
associations investigated, additional examination of statistically
significant associations using FDR control helped us to evaluate
the potential for chance findings due to multiple testing. Results
from the replication conducted within the US Kidney Cancer
study for rs507879 were not statistically significant on their own,
but the study (696 cases and 593 controls) was underpowered
(40%) to detect an association of 1.3. Point estimates calculated by
pooling data from the two studies may better represent the true
association between rs507879 and renal cancer.
In summary, the results from this study suggest that genetic
polymorphisms and haplotypes within the CASP1, CASP5, EGFR,
Table 5. Results from Replication of SNP rs507879 and Renal Cancer Risk.
SNP/
Genotypes CEERC
1 US Kidney (Whites only)1 Combined (Whites only)1 Combined (All)2,3
Cases Controls OR 95% CI Cases Controls OR 95% CI Cases Controls OR1 95% CI Cases Controls OR1 95% CI
CASP 1/5/4/12
rs507879 (T90A)
TT 212 337 1.00 208 190 1.00 420 527 1.00 458 590 1.00
CT 381 481 1.29 1.03–1.60 334 276 1.10 0.85–1.42 715 757 1.20 1.01–1.41 840 944 1.19 1.02–1.39
CC 179 209 1.39 1.07–1.82 154 127 1.10 0.80–1.49 333 336 1.25 1.02–1.53 440 472 1.28 1.07–1.54
CT+CC 1.31 1.07–1.61 1.10 0.87–1.39 1.22 1.04–1.42 1.22 1.05–1.41
p-trend 0.01 0.53 0.02 0.007
1Adjusted for age, sex and study center.
2Association among African-Americans in US Kidney Cancer Study (n = 270 cases and 384 controls, CT: OR: 1.23 (0.77–1.97); CC: OR: 1.37 (0.85–2.23); p-trend = 0.21.
3Adjusted for age, sex, center and race.
doi:10.1371/journal.pone.0004895.t005
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and IGFBP3 genes are associated with renal cancer risk. The
regions identified in this study appear to have functional relevance
in renal and other types of cancer. To our knowledge, this is one of
the largest evaluations of genetic susceptibility and renal cancer
conducted to date, but there is need to replicate and extend our
findings in other populations.
Supporting Information
Figure S1 Sliding window results and linkage disequilibrium
plot of CASP1/5/4/12 region. SNPs associated or located within
a CASP gene are indicated by their respective lines. The haplotype
results reported in Table 3 are indicated by a line depicting
Region1. Upper portion of figure presents global p-value
associated with each 3 SNP sliding window, unadjusted and
FDR-adjusted. Lower portion of figure presents linkage disequi-
librium plot with color scheme based on D’ and logarithm of the
odds of linkage (LOD) scores. Numbers in the squares are r2
values.
Found at: doi:10.1371/journal.pone.0004895.s001 (4.14 MB TIF)
Figure S2 Sliding window results and linkage disequilibrium
plot of EGFR region. The haplotype results for EGFR reported in
Table 3 are indicated by lines depicting each region. Upper
portion of figure presents global p-value associated with each 3
SNP sliding window, unadjusted and FDR-adjusted. Lower
portion of figure presents linkage disequilibrium plot with color
scheme based on D’ and logarithm of the odds of linkage (LOD)
scores. Numbers in the squares are r2 values.
Found at: doi:10.1371/journal.pone.0004895.s002 (5.86 MB TIF)
Figure S3 Sliding window results and linkage disequilibrium
plot of IGFBP3 region. The haplotype results reported in Table 3
are indicated by a line depicting each region. Upper portion of
figure presents global p-value associated with each 3 SNP sliding
window, unadjusted and FDR-adjusted. Lower portion of figure
presents linkage disequilibrium plot with color scheme based on D’
and logarithm of the odds of linkage (LOD) scores. Numbers in the
squares are r2 values.
Found at: doi:10.1371/journal.pone.0004895.s003 (3.22 MB TIF)
Table S1 Results from all Growth and Differentiation, Apopto-
sis Polymorphisms and Renal Cell Cancer Risk.
Found at: doi:10.1371/journal.pone.0004895.s004 (2.66 MB
DOC)
Table S2 EGFR integrated haplotype and renal cancer risk.
Found at: doi:10.1371/journal.pone.0004895.s005 (0.06 MB
DOC)
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